Search

ENPNewswire-November 18, 2024--Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo plus Yervoy for the First-Line Treatment of Adult Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer [...]

Opinion based on results from the Phase 3 CheckMate -8HW trial, in which the dual immunotherapy combination of Opdivo and Yervoy demonstrated statistically significant and clinically meaningful improvement in progression-free [...]

Reuters - EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection - 15/11/2024 The European Union's drugs regulator on Thursday recommended approval of Eisai (4523.T), opens new tab and Biogen's [...]

Financial Times - AbbVie shares tumble after schizophrenia drug disappoints - 11/11/2024 Shares in AbbVie tumbled after the drugmaker revealed that an experimental treatment for schizophrenia, the main drug purchased [...]

Reuters - Bristol Myers earnings beat expectations, driven by sales of older drugs - 31/10/2024 Bristol Myers Squibb (BMY.N), opens new tab reported a higher-than-expected third-quarter profit on Thursday, citing [...]

Financial Times - Jeff Smith, the activist picking a fight with Covid hero Pfizer - 26/10/2024 Taking to the stage this week in front of an annual gathering of activist [...]

PMLiVE - Roche's Alecensa receives NICE recommendation to treat ALK-positive lung cancer - 21/10/2024 Roche's Alecensa (alectinib) has been recommended by the National Institute of Health and Care Excellence (NICE) [...]

China Daily - Global Edition - AstraZeneca expanding R&D pipeline in China - 14/10/2024 In an interview with China Daily, Sharon Barr, executive vice-president of biopharmaceuticals R&D at AstraZeneca, said [...]

China Daily - AstraZeneca announces plans for new innovations for China - 30/9/2024 United Kingdom-based biopharmaceutical giant AstraZeneca will add 10 to 15 new projects to the company's research and [...]

These data represent the longest reported median overall survival from a Phase 3 advanced melanoma trial; data selected for official ESMO press conference At ten years, more than 40% (43%) [...]

ENPNewswire-September 12, 2024--Ono and Bristol-Myers Squibb KK Submit Supplemental Application of Opdivo and Yervoy in Combination Treatment in Japan to Expand the Use for Unresectable Advanced or Recurrent Microsatellite Instability-High [...]

PRINCETON: BRISTOL MYERS SQUIBB has issued the following news release: Bristol Myers Squibb (NYSE: BMY) today announced the presentation of nearly 60 abstracts of company-sponsored studies, investigator-sponsored studies, and collaborations [...]

ENPNewswire-September 10, 2024--Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- [...]

ENPNewswire-August 23, 2024--Bristol Myers Squibb Statement on Oncologic Drugs Advisory Committee Meeting to Discuss PD-L1 Expression Levels in Gastric and Esophageal Cancers (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 22082024 - [...]

Acceptance based on Phase 3 CheckMate -9DW trial results demonstrating improved survival with Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to investigator's choice of lenvatinib or sorafenib in this patient population [...]

ENPNewswire-August 12, 2024--Ono and Bristol-Myers Squibb KK Submit Supplemental Application of Opdivo and Yervoy in Combination Treatment in Japan to Expand the Use for Unresectable Hepatocellular Carcinoma (C)2024 ENPublishing - [...]

PRINCETON: Bristol Myers Squibb announced that the European Medicines Agency (EMA) validated its Type II variation application for Opdivo (nivolumab) plus Yervoy (ipilimumab) as a potential first-line treatment option for [...]

The Application is based on Phase 3 CheckMate -9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator's choice of lenvatinib or sorafenib in this patient population [...]

Financial Times - AstraZeneca drug fails to extend lives of breast cancer patients - 23/9/2024 Latest setback for Dato-DXd comes after disappointing results in lung cancer treatment earlier this month. [...]

Reuters - Sanofi, AstraZeneca win US approval for RSV therapy manufacturing line - 16/9/2024 Sanofi (SASY.PA), opens new tab and partner AstraZeneca (AZN.L), opens new tab have received approval from [...]

BioSpace - J&J Challenges AstraZeneca's Tagrisso With Phase III Data for Rybrevant, Lazcluze Combo - 9/9/2024 Johnson & Johnson on Sunday posted long-term follow-up data from the Phase III MARIPOSA [...]

Clinical Trials Arena - Bristol Myers Squibb's CAMZYOS offers benefits in oHCM trial - 2/9/2024 Bristol Myers Squibb (BMS) has unveiled new long-term follow-up results from the EXPLORER-LTE cohort of [...]

Financial Times - AstraZeneca threatens to move UK vaccine manufacturing to US - 23/8/2024 AstraZeneca has warned it could relocate its vaccine manufacturing site on Merseyside to Philadelphia amid a [...]

M2 EQUITYBITES-August 21, 2024-FDA accepts Bristol Myers Squibb's sBLA for first-line liver cancer treatment (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Biopharmaceutical company Bristol Myers Squibb (NYSE: BMY) announced on Wednesday that it [...]

M2 PHARMA-August 21, 2024-FDA accepts Bristol Myers Squibb's sBLA for first-line liver cancer treatment (C)2024 M2 COMMUNICATIONS Biopharmaceutical company Bristol Myers Squibb (NYSE: BMY) announced on Wednesday that it has [...]

The Pharmaletter - UK must get ready for new cell and gene therapies, says ABPI - 19/8/2024 The UK's National Health Service (NHS) got off to a good start with [...]

PRINCETON, N.J.--(BUSINESS WIRE)--Jun 21, 2024-- https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.bms.com%2F&esheet=54084533&newsitemid=20240621181118&lan=en-US&anchor=Bristol+Myers+Squibb&index=1&md5=e89b6dc343b4a54f3a0cd64f2009e546 (NYSE: BMY) today announced that the European Medicines Agency (EMA) has validated the extension application to introduce a new route of administration (subcutaneous use) [...]

Validation is based on results from CheckMate -67T, the first Phase 3 trial of the subcutaneous formulation of Opdivo to evaluate and demonstrate noninferior pharmacokinetics and efficacy vs. its intravenous [...]

ENPNewswire-June 5, 2024--Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma (C)2024 ENPublishing - [...]

Late-breaking exploratory analysis of the CheckMate -77T study of perioperative Opdivo shows improved event-free survival and pathologic complete response in stage III resectable NSCLC patients regardless of nodal status Four-year [...]

PRINCETON, N.J.--(BUSINESS WIRE)--May 29, 2024-- https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.bms.com%2F&esheet=54019755&newsitemid=20240528977107&lan=en-US&anchor=Bristol+Myers+Squibb&index=1&md5=1a7b332cb00fc4f955271aa0db1919f3 (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo ® (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment [...]

Approval based on results from CheckMate -901, the first Phase 3 trial in this patient population with an immunotherapy-chemotherapy combination to demonstrate survival benefit versus standard-of-care chemotherapy alone First concurrent [...]

PRINCETON, N.J.--(BUSINESS WIRE)--May 21, 2024-- https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.bms.com&esheet=54003298&newsitemid=20240520853296&lan=en-US&anchor=Bristol+Myers+Squibb&index=1&md5=ae9799a2b25761039bac4d157867f088 (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has reassigned the https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fnews.bms.com%2Fnews%2Fcorporate-financial%2F2024%2FU.S.-Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-Application-for-Subcutaneous-Nivolumab-nivolumab-and-hyaluronidase%2Fdefault.aspx&esheet=54003298&newsitemid=20240520853296&lan=en-US&anchor=previously+announced&index=2&md5=d3f297942eb569f3dcd04ce656be16f5 Prescription Drug User Fee Act (PDUFA) goal date [...]

Updated Prescription Drug User Fee Act (PDUFA) goal date of December 29, 2024 PRINCETON, N.J. -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration [...]

PRINCETON: Bristol Myers Squibb announced that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo(r) (nivolumab) plus Yervoy(r) (ipilimumab) for the first-line treatment of adult [...]

PRINCETON, N.J.--(BUSINESS WIRE)--May 6, 2024-- https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.bms.com%2F&esheet=53972080&newsitemid=20240503935677&lan=en-US&anchor=Bristol+Myers+Squibb&index=1&md5=3bbf6241bfc1bddaa9580fc1a33d79ec (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for the subcutaneous formulation of [...]